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Abstract
Background: Chromatin immunoprecipitation (ChIP) has become a very popular technique to
study epigenetic regulation because it can be used to identify proteins and protein modifications
present at specific locations in chromatin. While techniques have been developed to investigate
epigenetic modifications present in chromatin during a specific biological function such as
transcription, they depend upon the ability of the ChIP to analyze two epitopes on the same
chromatin and are generally time consuming, difficult to perform, and not very sensitive. The Dual
Agarose Magnetic (DAM) ChIP procedure described here is designed to address these
shortcomings.
Findings: Protein A agarose and protein G magnetic beads bound with different IgGs have been
combined in a single Chromatin Immunoprecipitation (ChIP) assay to analyze for the presence of
two epitopes on the same chromatin at the same time. This procedure has been used with non-
immune rabbit IgG bound to either the agarose or beads in order to include an internal negative
control for non-specific binding of chromatin. The procedure has also been used with various
antibodies including those targeting RNA Polymerase II and replication protein A 70 to determine
whether specific forms of modified histones are present in either transcribing or replicating forms
of SV40 minichromosomes respectively.
Conclusions: The DAM ChIP procedure is a rapid, simple, and sensitive technique to characterize
two epitopes located in the same chromatin. It should be particularly useful for the rapid screening
of epigenetic modifications present in biologically active chromatin.
Findings
Chromatin Immunoprecipitation (ChIP) has become an
extremely powerful tool for the characterization of biolog-
ically functional chromatin. Specific antibodies bound to
either protein A agarose or protein G magnetic beads are
used to immune-select fragments of chromatin contain-
ing the target epitope of the antibody followed by PCR
amplification to identify and quantitate the DNA present
in the chromatin [1-4]. A carrier like agarose or magnetic
beads is required in both of these procedures because it is
necessary to separate the chromatin bound to antibody
from contaminating chromatin during purifications. In
the standard procedure this is done by sedimenting the
agarose by low speed centrifugation, while in the modifi-
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cation with magnetic beads a magnet is used to bind the
beads.
We have taken advantage of the distinct properties of aga-
rose and magnetic beads and developed a procedure
which allows chromatin immunoprecipitation with two
antibodies present in the same tube. A schematic repre-
sentation of this procedure is shown in Figure 1. One of
the antibodies is bound to agarose, while the second anti-
body is bound to magnetic beads. Following binding of
the chromatin to one of the antibodies and addition of
the other antibody, the agarose and magnetic beads are
separated based upon their difference in magnetic proper-
ties.
We first determined whether normal rabbit IgG and anti-
body to hyperacetylated histone H4 (Hyp H4) when
bound to different carriers in the same ChIP would still
function as they do in typical ChIP assays. We have exten-
sively studied the chromatin structure of SV40 minichro-
mosomes and showed that they contain hyperacetylated
histones [5-7]. All ChIPs were performed using a Milli-
pore ChIP assay kit (17-295) with binding and washing
conditions as previously described [5-7]. Antibody to Hyp
Schematic for Dual Agarose Magnetic (DAM) ChIP protocol Figure 1
Schematic for Dual Agarose Magnetic (DAM) ChIP protocol.BMC Research Notes 2009, 2:250 http://www.biomedcentral.com/1756-0500/2/250
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H4 and normal rabbit IgG were incubated in 750 μl of
ChIP dilution buffer (CDB) and either 80 μl of protein A
agarose or 25 μl of protein G magnetic beads for from 4
hours. Following the binding step, unbound serum con-
stituents were removed from the agarose and magnetic
beads by low speed centrifugation and interaction with a
magnet in a stand (Promega; Z5342), respectively. The
supernatants were removed and the agarose and magnetic
beads resuspended in 100 μl of ChIP dilution buffer.
For standard ChIPs the resuspended agarose and magnetic
beads carrying either IgG or antibody to Hyp H4 were
added to 650 μl of CDB in an Eppendorf tube. Purified
SV40 minichromosomes [5-7] {75 μl} were added and
the assay was incubated at 4°C with constant end over
end rotation over night. The chromatins bound to agarose
and magnetic beads were purified, eluted from each car-
rier with two 15 minute incubations using the SDS lysis
buffer in the Millipore kit, and analyzed as previously
described [5-7].
As expected from our previous studies [5-7], there was
very little if any PCR amplification product in the samples
from chromatin bound to IgG (Figure 2A; lanes 1 and 3)
and significant product formation in samples from chro-
matin bound to Hyp H4 (lanes 2 and 4).
For DAM ChIPs 100 μl of agarose containing IgG and 100
μl of magnetic beads containing Hyp H4 were added to an
Eppendorf tube containing 550 μl of CDB. Similarly, in a
separate tube 100 μl of magnetic beads containing IgG
and 100 μl of agarose containing Hyp H4 were added to
550 μl of CDB. SV40 minichromosomes {150 μl} were
added to each of the tubes and the assay incubated as
above. Following incubation overnight, the agarose and
magnetic beads were separated. The tubes were placed
adjacent to a magnet stand for 2 minutes. The supernatant
including the agarose was then removed and transferred
to a new tube also in the magnet stand. The magnetic
beads were washed once with 100 μl of CDB and the wash
liquid added to the new tube. Following a further 2 min-
utes to remove any remaining magnetic beads the super-
natant containing the agarose was again transferred to a
new tube. The agarose was sedimented by low speed cen-
trifugation and the liquid removed. The tubes containing
magnetic beads and agarose were then washed and the
chromatin eluted and prepared as described above.
The results of this analysis are shown in Figure 2B. Again
we observed very little amplification of DNA present in
IgG bound chromatin (lanes 1 and 3) and extensive
amplification of the DNA present in the Hyp H4 bound
chromatin (lanes 2 and 4). The similarity in results
between Figure 2A indicate that both the agarose and
magnetic beads carrying IgG or antibody function
together in the DAM ChIP assay the same as when they are
separate in a standard ChIP assay. It is not clear why there
is more amplification with the IgG bound to magnetic
beads than agarose.
Next, we investigated whether DAM ChIPs could be used
to determine whether two different proteins or protein
modifications can be observed in the same SV40 mini-
chromosomes. The DAM ChIP strategy that we used to
demonstrate this is shown in Figure 3. An SV40 minichro-
mosome containing two epitopes of interest, X and Y, is
shown in part A. While the schematic will be described
using an antibody to protein X bound to the magnetic
beads and an antibody to protein Y bound to agarose, the
DAM ChIP can also be performed with the antibody to
protein X bound to the agarose beads and an antibody to
protein Y bound to magnetic beads.
In the first step, a pool of SV40 minichromosomes iso-
lated from infected cells was immune selected with anti-
body to X bound to magnetic beads and the magnetic
beads containing the selected minichromosomes washed
according to the Millipore protocol to remove the con-
taminating SV40 minichromosomes lacking this epitope
(Part B). In the second step antibody to Y bound to agar-
ose was added and incubated overnight with end over end
rotation. We hypothesized that if a minichromosome
bound to the magnetic beads also contained the protein
target for the second antibody in an accessible location,
that portion of the fragment containing the antibody tar-
get would be bound by the antibody on the second carrier
and would ultimately be transferred to it as a result of
shearing of the chromatin (Part C). Following the incuba-
tion, the magnetic beads were separated from the agarose
and the agarose was subsequently washed according to
the Millipore protocol. The bound chromatin was eluted
from the agarose using the Millipore lysis buffer and pre-
pared for PCR analysis.
Typical results of this analysis are also shown in Figure 2C
and 2D. Antibody to Hyp H4 was either bound to mag-
netic beads for the first step (C) or agarose (D). Normal
IgG or antibody to hyperacetylated histone H3 (Hyp H3)
bound to either agarose or magnetic beads was used as the
second antibody. We used IgG as a negative control for
non-specific binding and antibody to Hyp H3 as a posi-
tive control since we have already shown that Hyp H4 and
Hyp H3 can be found together on SV40 minichromo-
somes [5,8,9]. As shown in this figure we observed a
robust amplification product from the chromatin present
on the carriers with antibody to Hyp H3 (lane 2, C and D)
and very little amplification product from any chromatin
bound to IgG (lane 1 C and D) regardless of which carrierBMC Research Notes 2009, 2:250 http://www.biomedcentral.com/1756-0500/2/250
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was used in the first and second steps indicating that both
Hyp H4 and Hyp H3 were present in the same SV40 min-
ichromosomes using the DAM procedure.
Finally, we analyzed replicating and transcribing SV40
minichromosomes for the presence of modified histones
(Figure 4). Using ChIP validated antibodies to replication
protein A 70 (RPA70) [7] and RNA Polymerase II
(RNAPII) [9] to immune select replicating and transcrib-
ing SV40 full length minichromosomes respectively, we
analyzed the minichromosomes for the presence of his-
tone H3 mono-methyl lysine 9 (H3K9me1), histone H3
di-methyl lysine 9 (H3K9me2), histone H3 tri-methyl
lysine 9 (H3K9me3) and Hyp H4 with the corresponding
antibodies. All these antibodies except for H3K9me2
which was a mouse monoclonal antibody were rabbit pol-
DAM ChIPs Figure 2
DAM ChIPs. 48 hour unfixed SV40 minichromosomes were analyzed by (a) standard (Std ChIP) or (b, c, d) DAM chromatin 
immunoprecipitation (DAM ChIP) and the immunoprecipitates were amplified by PCR (32 cycles) with primer sets to the early 
region of the SV40 genome as previously described [5-7]. (a) Std ChIPs with antibodies bound to protein A agarose or protein 
G magnetic beads. Lane 1, Std ChIP with IgG (7.5 μl) (Bethyl Laboratories; P120-101) bound to agarose (Millipore, 17-295); 
lane 2, Std ChIP with Hyp H4 (7.5 μl) (Millipore; 06-866) bound to agarose; lane 3, Std ChIP with IgG (7.5 μl) bound to mag-
netic beads (Active Motif, 53014); lane 4, Std ChIP with Hyp H4 (7.5 μl) bound to magnetic beads. Ag; Agarose, MB; magnetic 
beads. (b) DAM ChIPs in which chromatin was analyzed with IgG (7.5 μl) bound to agarose (Lane 1) and Hyp H4 (7.5 μl) bound 
to magnetic beads (Lane 2) in the same tube or IgG (7.5 μl) bound to magnetic beads (Lane 3) and Hyp H4 (7.5 μl) bound to 
agarose (Lane 4) in the same tube. (c) DAM ChIPs immune selected with antibody to Hyp H4 bound to magnetic beads. Puri-
fied immune selected chromatin was divided into two aliquots and an aliquot was added to a tube containing either IgG or Hyp 
H3 bound to agarose. Lane 1, DAM ChIP with IgG (7.5 μl); lane 2, DAM ChIP with Hyp H3 (7.5 μl) (Millipore; 06-599). DAM 
ChIPs immune selected with antibody to Hyp H4 bound to agarose. Purified immune selected chromatin was divided into two 
aliquots and an aliquot was added to a tube containing either IgG or Hyp H3 bound to magnetic beads. Lane 1, DAM ChIP with 
IgG (7.5 μl); lane 2, DAM ChIP with Hyp H3 (7.5 μl).BMC Research Notes 2009, 2:250 http://www.biomedcentral.com/1756-0500/2/250
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yclonal antibodies. In standard ChIPs all of these antibod-
ies recognize SV40 minichromosomes isolated at this
time and yield robust amplification products (Figure 4A,
lanes 2 through 5). When replicating minichromosomes
(Figure 4B, RPA70 Primary ChIP) were analyzed, we
observed robust amplification products from the DAM
ChIPs with antibody to H3K9me1 (lane 2), H3K9me2
(lane 3), and Hyp H4 (lane 5), but not from the DAM
ChIPs with the negative control IgG (lane 1) or antibody
to H3K9me3 (lane 4). When transcribing minichromo-
somes (Figure 4B, RNAPII Primary ChIP) were analyzed,
we observed a weak but definite amplification product in
the Hyp H4 DAM ChIP (lane 5) and very weak amplifica-
tion products from all of the other DAM ChIPs. These
results indicated that replicating minichromosomes con-
tained Hyp H4 as previously reported [7], H3K9me1, and
Schematic representation of the strategy used for DAM ChIP analysis of protein modifications in immune selected SV40 mini- chromosomes Figure 3
Schematic representation of the strategy used for DAM ChIP analysis of protein modifications in immune 
selected SV40 minichromosomes.BMC Research Notes 2009, 2:250 http://www.biomedcentral.com/1756-0500/2/250
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H3K9me2 but not H3K9me3. In contrast transcribing
minichromosomes appeared to contain Hyp H4 as previ-
ously observed [9] and little if any of the methylated
forms of H3K9. The lack of methylated H3K9 is not sur-
prising since this modification is thought to be repressive
[10].
We have demonstrated the feasibility of using two anti-
bodies which are individually bound to different carriers
in a single ChIP assay and present evidence that this strat-
egy can be used either to include an internal negative con-
trol during an assay or to determine whether two proteins
or protein modifications can be located in a large frag-
DAM ChIP analysis of replicating and transcribing SV40 minichromosomes Figure 4
DAM ChIP analysis of replicating and transcribing SV40 minichromosomes. 48 hour unfixed SV40 minichromo-
somes were analyzed by [a] standard chromatin immunoprecipitation using either IgG, or antibodies to H3K9me1, H3K9me2, 
H3K9me3, or Hyp H4 (7.5 μl each) bound to protein A agarose or [b] DAM ChIPs using antibody bound to magnetic beads in 
the first step which recognized RPA70 (SCBT; sc-25376) (50 μl) to immune select replicating minichromosomes or antibody 
which recognized RNAPII (SCBT; sc-900) (50 μl) to immune select transcribing minichromosomes. Following immune selec-
tion the magnetic beads were washed according to protocol and then divided into five equal aliqouts with an aliquot added to 
a tube which contained either IgG, or antibodies to H3K9me1, H3K9me2, H3K9me3, or Hyp H4 (7.5 μl each) bound to agar-
ose. The immunoprecipitates bound to agarose from both analyses were then amplified by PCR (a: 32 cycles or b: 45 cycles) 
with primer sets to the early region of the SV40 genome as previously described [5-7]. Lane 1, ChIP with IgG; lane 2, ChIP with 
H3K9me1 (Abcam; ab9045); lane 3, ChIP with H3K9me2 (Abcam; ab1220); lane 4, ChIP with H3K9me3 (Abcam; ab8898); lane 
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ment of chromatin. The advantages of the former proce-
dure are that only half as much input chromatin is
required, the washes can be performed while the two car-
riers are together, and the binding conditions for the neg-
ative control and test antibody are identical. The major
advantage of DAM ChIPs is its simplicity. The procedure
is relatively rapid and unlike most other procedures like
ReChIP [11] does not require an elution step. After pre-
paring our manuscript we became aware of a similar tech-
nique which was independently developed in another
laboratory at the same time [12]. While the basic concept
of using two different carriers for antibodies is similar in
both our procedure and the procedure from the Medeiros
group [12], we believe the two procedures differ signifi-
cantly. Conceptually the Medeiros procedure is designed
as a true sequential ChIP which utilizes the high affinity
of the biotin-streptavidin interaction in conjunction with
short incubation times and fragmented chromatin to
allow the magnetic beads containing biotin conjugated
antibody to bind more tightly to the chromatin present on
agarose than the antibody originally present on the agar-
ose. Thus, the authors report that they observe direct inter-
actions between the magnetic beads and agarose and that
the chromatin is essentially transferred from the agarose
to the magnetic beads during the procedure. Our proce-
dure is not a true sequential ChIP. Instead, it is based
upon the concept that a large fragment of chromatin
bound at two distant sites by different antibodies present
on carriers will be sheared due to rotation during the rel-
atively long incubation into smaller fragments bound to
each of the antibodies. For this reason we have never
observed direct interactions between the magnetic beads
and agarose during ChIPs. The two procedures also differ
in the following ways: (i) Our procedure does not require
biotin conjugated antibodies for ChIPs since the antibod-
ies used in the DAM ChIP are bound directly to Protein A
agarose or Protein G magnetic beads; (ii) The DAM ChIP
protocol looks at protein binding over a much larger
sequence (~5000 bp) whereas the technique described by
Medeiros et al primarily looks at proteins bound to pro-
moter sequences, which are smaller in size (1000 bp or
less); (iii) Extensive sonication of chromatin is not
required in the DAM ChIP procedure; (iv) Finally, we
show similar results using the DAM ChIP technique
regardless of which carrier is used for the first or second
antibody. Using this technique we also observed no cross
contamination with either of the carriers. Considering the
significant advantages of the DAM ChIP protocol we
anticipate this modified technique will be a useful tool for
the study of epigenetic modification.
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